Pathophysiology of diabetic erectile dysfunction: potential contribution of vasa nervorum and advanced glycation endproducts.
Erectile dysfunction (ED) due to diabetes mellitus remains difficult to treat medically despite advances in pharmacotherapeutic approaches in the field. This unmet need has resulted in a recent re-focus on the pathophysiology, in order to understand the cellular and molecular mechanisms leading to ED in diabetes. Diabetes-induced ED is often resistant to PDE5 inhibitor treatment, thus there is a need to discover targets that may lead to novel approaches for a successful treatment. The aim of this brief review is to update the reader in some of the latest development on that front, with a particular focus on the role of impaired neuronal blood flow and the formation of advanced glycation endproducts.
Department of Translational Medicine, Cranfield Health, Cranfield University, Bedfordshire, UK. s.cellek@cranfield.ac.uk
S
S
Cellek
N E
NE
Cameron
M A
MA
Cotter
A
A
Muneer
D003929:Diabetic Neuropathies / Q000378:metabolism / Q000503:physiopathology*; D007172:Erectile Dysfunction / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006801:Humans; D008297:Male; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use; D014650:Vasa Nervorum / Q000378:metabolism / Q000503:physiopathology*
D017127:Glycation End Products, Advanced; D058986:Phosphodiesterase 5 Inhibitors